BioSpace News Archive

Experts are predicting a record-breaking rush of IPOs this fall as companies flood to the Nasdaq.

A recent study suggests that about one-third of cancer indications with Accelerated Approval pathways are still on product labels without follow-up studies confirming their benefits.

SENS Research Foundation released findings that confirmed the charges of inappropriate behavior raised by two former female employees against Aubrey de Grey.

Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.

Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 16-21, 2021.

Management to Host Conference Call on Monday, September 20, 2021 at 4:00 p.m. ET

InMed Pharmaceuticals Inc. today announced that it has entered into a definitive agreement (“Definitive Agreement”) to acquire BayMedica Inc.

Provention Bio, Inc. today provided an update on the status and timing of its ongoing efforts to address FDA considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021.

Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA ® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate

BELLUS Health Inc. today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough (“RCC”).